Utilities and other high yielding sectors are reaching overbought levels, so investors may want to rotate into biotechs, says TheStreet's Jim Cramer. Cramer said packaged-goods companies and REITs have reached their 'outer-limits' and the money in those areas may gravitate to biotech stocks that have been pressured in the past year. Cramer highlighted a bullish call by RealMoney technical strategist Bruce Kamich on Regeneron (REGN) , saying the stock is poised for a major breakout. Regeneron reports quarterly earnings on Thursday before the open.
More from Video
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.